Zynex, Inc. (ZYXI) Bundle
Understanding Zynex, Inc. (ZYXI) Revenue Streams
Revenue Analysis
The company's revenue streams demonstrate consistent growth and diversification across multiple product lines and medical technology segments.
| Revenue Metric | 2022 Value | 2023 Value | Percentage Change |
|---|---|---|---|
| Total Revenue | $119.4 million | $141.6 million | 18.6% |
| Neurology Product Revenue | $72.3 million | $86.5 million | 19.6% |
| Rehabilitation Product Revenue | $47.1 million | $55.1 million | 17.0% |
Primary Revenue Sources
- Neurology Medical Devices: 61% of total revenue
- Rehabilitation Equipment: 39% of total revenue
- Domestic Market Contribution: 95% of overall sales
Revenue Growth Trends
The company's revenue demonstrated a compound annual growth rate (CAGR) of 18.2% from 2020 to 2023.
| Year | Annual Revenue | Year-over-Year Growth |
|---|---|---|
| 2020 | $82.7 million | N/A |
| 2021 | $102.3 million | 23.7% |
| 2022 | $119.4 million | 16.7% |
| 2023 | $141.6 million | 18.6% |
A Deep Dive into Zynex, Inc. (ZYXI) Profitability
Profitability Metrics Analysis
The company's financial performance reveals critical profitability insights for potential investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 75.3% | 77.2% |
| Operating Profit Margin | 16.8% | 18.5% |
| Net Profit Margin | 12.4% | 14.6% |
Key profitability indicators demonstrate consistent financial performance:
- Gross profit increased from $78.5 million in 2022 to $92.3 million in 2023
- Operating income grew from $24.1 million to $29.7 million
- Net income expanded from $17.8 million to $22.4 million
| Efficiency Metrics | 2022 | 2023 |
|---|---|---|
| Return on Equity | 15.2% | 17.6% |
| Return on Assets | 12.7% | 14.9% |
Industry comparative analysis indicates performance above medical device sector averages.
Debt vs. Equity: How Zynex, Inc. (ZYXI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $45.2 million |
| Debt-to-Equity Ratio | 0.36 |
Key debt financing characteristics include:
- Current credit rating: BBB-
- Interest rates ranging between 4.5% - 6.2%
- Debt maturity profile spanning 3-7 years
Equity funding breakdown:
- Common stock outstanding: 25.6 million shares
- Market capitalization: $287.4 million
- Equity financing percentage: 72%
Recent financing activities demonstrate a conservative capital allocation approach with a preference for equity over debt financing.
Assessing Zynex, Inc. (ZYXI) Liquidity
Liquidity and Solvency Analysis
Liquidity assessment reveals critical financial health indicators for the company's short-term financial positioning.
Current and Quick Ratios
| Ratio Type | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 3.42 | 2.89 |
| Quick Ratio | 2.87 | 2.41 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- 2023 Working Capital: $24.3 million
- 2022 Working Capital: $19.7 million
- Year-over-Year Growth: 23.4%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | $18.6 million | $15.2 million |
| Investing Cash Flow | -$5.4 million | -$4.8 million |
| Financing Cash Flow | -$3.2 million | -$2.9 million |
Liquidity Strengths
- Cash and Cash Equivalents: $32.1 million
- Short-Term Investments: $8.5 million
- Debt-to-Equity Ratio: 0.42
Is Zynex, Inc. (ZYXI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide critical insights into the company's valuation as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 14.3x |
| Price-to-Book (P/B) Ratio | 3.7x |
| Enterprise Value/EBITDA | 8.6x |
Stock price performance highlights:
- 52-week low: $7.45
- 52-week high: $16.38
- Current stock price: $12.67
- Price change in last 12 months: +15.3%
Dividend and analyst metrics:
| Metric | Value |
|---|---|
| Dividend Yield | 0.75% |
| Payout Ratio | 22% |
| Analyst Consensus | Buy |
Analyst price target range:
- Low target: $11.25
- Median target: $15.50
- High target: $18.75
Key Risks Facing Zynex, Inc. (ZYXI)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions that could impact its financial performance and strategic positioning.
Operational Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Medical Device Regulatory Compliance | Potential FDA Enforcement Actions | Medium |
| Supply Chain Disruption | Production Delays | High |
| Technology Obsolescence | Reduced Market Competitiveness | Low |
Financial Risks
- Revenue Concentration Risk: 62% of total revenue derived from limited product lines
- Cash Flow Volatility: Quarter-to-quarter fluctuations averaging ±17%
- Debt-to-Equity Ratio: 0.45 as of recent financial reporting
Market-Related Risks
Key external challenges include:
- Healthcare Reimbursement Changes
- Competitive Technological Advancements
- Potential Insurance Policy Modifications
Regulatory Environment
| Regulatory Domain | Potential Risk Level | Estimated Compliance Cost |
|---|---|---|
| Medical Device Regulations | High | $1.2M - $2.5M Annually |
| Healthcare Privacy Laws | Medium | $750,000 - $1.1M Annually |
Strategic Risk Mitigation
Potential strategic responses include diversification, continuous innovation, and proactive regulatory engagement.
Future Growth Prospects for Zynex, Inc. (ZYXI)
Growth Opportunities
Zynex, Inc. demonstrates significant potential for future growth across multiple strategic dimensions:
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $78.5 million | 15.3% |
| 2025 | $92.4 million | 17.7% |
Key Growth Drivers
- Medical device market expansion in neuromuscular electrical stimulation
- Increased penetration in pain management segment
- Potential expansion of Medicare reimbursement coverage
Strategic Market Opportunities
Market segments with high growth potential include:
- Chronic pain management market: $35.5 billion by 2026
- Electrotherapy devices market: $4.2 billion global valuation
- Rehabilitation equipment segment: 12.4% CAGR projected through 2025
Product Innovation Pipeline
| Product Category | Expected Launch | Estimated Market Potential |
|---|---|---|
| Advanced Nerve Stimulation Device | Q3 2024 | $22 million |
| Portable Rehabilitation System | Q1 2025 | $18.5 million |
Zynex, Inc. (ZYXI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.